Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This phase 2, open label, dose escalation study is designed to evaluate the safety,
tolerability and efficacy of various doses of STP705 administered as localized injection in
patients with Basal Cell Carcinoma (BCC).
Goals:
- To determine the safe and effective recommended dose of STP705 for the treatment of
basal cell carcinoma.
- Analysis of biomarkers common to BCC formation pathway including TGF-β1 and COX-2.